ArticleInflammopharmacology2025
Fabrication of bergapten loaded microneedle patch and assessment of its anti-arthritic potential against complete Freund's adjuvant induced arthritis in Wistar rat.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research study was designed to fabricate bergapten-loaded biodegradable microneedle patches (BP-MNPs) and assess its anti-arthritic potential. The BP-MNPs were synthesized by solvent casting technique using polyvinyl pyrrolidone (PVP) and polyvinyl alcohol (PVA) as polymers, followed by their characterization. The in vitro release study and stability study were also conducted. X-ray diffraction analysis of BP-MNPs showed a broad range of crystallographic planes, while SEM analysis showed unfractured, sharp tips with a length of 500 µm and a base of 200 µm. The anti-arthritic potential of BP-MNPs was investigated by inserting 0.15 ml of Complete Freund's adjuvant (CFA) into the tail vein of Wistar rats on day 1 to develop a CFA-induced arthritic model. Treatment begins on the 8th day and continues till the 28th day. Methotrexate was administered orally (1 mg/kg) as the standard treatment. The BP-MNPs significantly (p < 0.001-0.0001) decreased paw swelling, arthritic scoring, pain, and restored body weight compared to orally administered bergapten and the standard treatment. The blood parameters were also restored by BP-MNPs, along with the restoration of oxidative stress biomarkers in liver homogenate and neurotransmitter levels in sciatic nerve homogenate. Treatment with BP-MNPs notably (p < 0.0001) reduced the mRNA expression of IL-6, COX-2, TNF-α, and NF-κB, while upregulating IL-4 in contrast to disease control and standard treatment groups. Treatment with BP-MNPs also improved the histology of the ankle joint and sciatic nerve. It can be concluded from the current study data that BP-MNPs at a dose of 10 mg/kg exhibited significant anti-arthritic and anti-nociceptive responses in arthritic rats in contrast to bergapten and the standard drug.
Indexed as
Identifiers
41065958What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.